Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis
ConclusionMost first-use ATs were effective for patients with ASUC, while second-use ATs might have had limited benefits in inducing CR. These findings may contribute to considerations for the management of hospitalized patients. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - October 13, 2023 Category: Gastroenterology Source Type: research
Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study
CONCLUSION: Darvadstrocel is a safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.PMID:37823920 | DOI:10.1007/s00508-023-02283-4 (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 12, 2023 Category: General Medicine Authors: Christopher Dawoud Kerstin Melanie Widmann Sascha Czipin Michael Pramhas Martina Scharitzer Anton Stift Felix Harpain Stefan Riss Source Type: research
Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study
CONCLUSION: Darvadstrocel is a safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.PMID:37823920 | DOI:10.1007/s00508-023-02283-4 (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 12, 2023 Category: General Medicine Authors: Christopher Dawoud Kerstin Melanie Widmann Sascha Czipin Michael Pramhas Martina Scharitzer Anton Stift Felix Harpain Stefan Riss Source Type: research
Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study
CONCLUSION: Darvadstrocel is a safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.PMID:37823920 | DOI:10.1007/s00508-023-02283-4 (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 12, 2023 Category: General Medicine Authors: Christopher Dawoud Kerstin Melanie Widmann Sascha Czipin Michael Pramhas Martina Scharitzer Anton Stift Felix Harpain Stefan Riss Source Type: research
Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study
CONCLUSION: Darvadstrocel is a safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.PMID:37823920 | DOI:10.1007/s00508-023-02283-4 (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - October 12, 2023 Category: General Medicine Authors: Christopher Dawoud Kerstin Melanie Widmann Sascha Czipin Michael Pramhas Martina Scharitzer Anton Stift Felix Harpain Stefan Riss Source Type: research
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
Conclusion: Our results demonstrate there is a considerable amount of comparative RWE for apixaban, rivaroxaban, and etanercept but limited comparative RWE for the other drugs set to undergo CMS price negotiations in 2026; additionally, our findings set up a number of next steps (e.g., risk of bias assessments) for further exploration of the available evidence base. Overall, CMS and manufacturers should consider proactively generating high-quality comparative RWE studies in the Medicare population to ensure that future price negotiations are based on robust evidence.PMID:37815792 | DOI:10.57264/cer-2023-0125 (Source: Journ...
Source: Journal of Comparative Effectiveness Research - October 10, 2023 Category: General Medicine Authors: Ashley Jaksa Patrick J Arena Nicolle Gatto Source Type: research
The CMS Reveals First 10 Drugs for Medicare Drug Negotiation
The long-awaited list of the first 10 Part D drugs to be included in the new Medicare Price Negotiation process includes the commonly prescribed rheumatology drugs Enbrel and Stelara. Initial negotiations with the drug manufacturers will begin this fall. (Source: The Rheumatologist)
Source: The Rheumatologist - October 9, 2023 Category: Rheumatology Authors: From the College Tags: Practice Support drug pricing Medicare Price Negotiation Source Type: research
Upadacitinib and ustekinumab combination treatment for a refractory case of spondyloarthritis and Crohn's disease
Clin Exp Rheumatol. 2023 Oct 5. doi: 10.55563/clinexprheumatol/qsy3kc. Online ahead of print.NO ABSTRACTPMID:37812461 | DOI:10.55563/clinexprheumatol/qsy3kc (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - October 9, 2023 Category: Rheumatology Authors: Elena Bianchi Anna Paola Pata Luca Cantarini Bruno Frediani Stefano Gentileschi Source Type: research
